These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 22793038)

  • 1. Living alone, obesity and smoking: important factors for quality of life after radiotherapy and androgen deprivation therapy for prostate cancer.
    Dieperink KB; Hansen S; Wagner L; Johansen C; Andersen KK; Hansen O
    Acta Oncol; 2012 Jul; 51(6):722-9. PubMed ID: 22793038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer.
    Ferrer M; Suárez JF; Guedea F; Fernández P; Macías V; Mariño A; Hervas A; Herruzo I; Ortiz MJ; Villavicencio H; Craven-Bratle J; Garin O; Aguiló F;
    Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):421-32. PubMed ID: 18325680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensity-modulated radiotherapy causes fewer side effects than three-dimensional conformal radiotherapy when used in combination with brachytherapy for the treatment of prostate cancer.
    Forsythe K; Blacksburg S; Stone N; Stock RG
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):630-5. PubMed ID: 22099032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease-specific symptoms and general quality of life of patients with prostate carcinoma before and after primary three-dimensional conformal radiotherapy.
    Staff I; Salner A; Bohannon R; Panatieri P; Maljanian R
    Cancer; 2003 Dec; 98(11):2335-43. PubMed ID: 14635067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensity-modulated radiotherapy to the pelvis and androgen deprivation in men with locally advanced prostate cancer: a study of adverse effects and their relation to quality of life.
    Lilleby W; Stensvold A; Dahl AA
    Prostate; 2013 Jul; 73(10):1038-47. PubMed ID: 23532709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study.
    Zapatero A; Valcárcel F; Calvo FA; Algás R; Béjar A; Maldonado J; Villá S
    J Clin Oncol; 2005 Sep; 23(27):6561-8. PubMed ID: 16170164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health-related quality of life in Japanese men with localized prostate cancer: assessment with the SF-8.
    Sugimoto M; Takegami M; Suzukamo Y; Fukuhara S; Kakehi Y
    Int J Urol; 2008 Jun; 15(6):524-8. PubMed ID: 18422571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health-related quality of life and treatment outcomes for men with prostate cancer treated by combined external-beam radiotherapy and hormone therapy.
    Hashine K; Azuma K; Koizumi T; Sumiyoshi Y
    Int J Clin Oncol; 2005 Feb; 10(1):45-50. PubMed ID: 15729601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for localized prostate cancer.
    Frank SJ; Pisters LL; Davis J; Lee AK; Bassett R; Kuban DA
    J Urol; 2007 Jun; 177(6):2151-6; discussion 2156. PubMed ID: 17509305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health-related quality of life after adjuvant and salvage postoperative radiotherapy for prostate cancer - a prospective analysis.
    Pinkawa M; Fischedick K; Asadpour B; Gagel B; Piroth MD; Holy R; Krenkel B; Eble MJ
    Radiother Oncol; 2008 Jul; 88(1):135-9. PubMed ID: 18022263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross validation of the prostate cancer radiotherapy late toxicity (PCRT) questionnaire with the expanded prostate cancer index composite (EPIC) instrument.
    Rodrigues G; Bauman G; Venkatesan V; Ahmad B; Lock M; Sexton T; D'Souza D; Stitt L; Eid S
    Can J Urol; 2011 Aug; 18(4):5802-10. PubMed ID: 21854712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health-related quality of life in patients with locally advanced prostate cancer after 76 Gy intensity-modulated radiotherapy vs. 70 Gy conformal radiotherapy in a prospective and longitudinal study.
    Lips I; Dehnad H; Kruger AB; van Moorselaar J; van der Heide U; Battermann J; van Vulpen M
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):656-61. PubMed ID: 17512127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-sectional survey of long-term quality of life after radical perineal prostatectomy.
    Yang BK; Crisci A; Young MD; Silverstein AD; Peterson BL; Dahm P
    Urology; 2005 Jan; 65(1):120-5. PubMed ID: 15667876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical response after 3-d conformal radiotherapy of localized prostate cancer to a total dose of 66 gy 4-year results.
    Wachter-Gerstner N; Wachter S; Goldner G; Nechvile E; Pötter R
    Strahlenther Onkol; 2002 Oct; 178(10):542-7. PubMed ID: 12386785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of volume and location of irradiated rectum wall on rectal blood loss after radiotherapy of prostate cancer.
    Koper PC; Heemsbergen WD; Hoogeman MS; Jansen PP; Hart GA; Wijnmaalen AJ; van Os M; Boersma LJ; Lebesque JV; Levendag P
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1072-82. PubMed ID: 15001247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective quality of life study in patients with locally advanced prostate cancer, treated with radiotherapy with or without regional or interstitial hyperthermia.
    Van Vulpen M; De Leeuw JR; Van Gellekom MP; Van Der Hoeven J; De Graeff A; Van Moorselaar RJ; Van Der Tweel I; Hofman P; Lagendijk JJ; Battermann JJ
    Int J Hyperthermia; 2003; 19(4):402-13. PubMed ID: 12850926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sexual function after stereotactic body radiotherapy for prostate cancer: results of a prospective clinical trial.
    Wiegner EA; King CR
    Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):442-8. PubMed ID: 20137864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bother problems in prostate cancer patients after curative treatment.
    Stensvold A; Dahl AA; Brennhovd B; Småstuen MC; Fosså SD; Lilleby W; Steinsvik A; Axcrona K; Smeland S
    Urol Oncol; 2013 Oct; 31(7):1067-78. PubMed ID: 22341412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delayed rectal and urinary symptomatology in patients treated for prostate cancer by radiotherapy with or without short term neo-adjuvant androgen deprivation.
    Christie D; Denham J; Steigler A; Lamb D; Turner S; Mameghan H; Joseph D; Matthews J; Franklin I; Atkinson C; North J; Poulsen M; Spry NA; Tai KH; Wynne C; Duchesne G; Kovacev O; Francis L; Kramar A; D'Este C; Bill D
    Radiother Oncol; 2005 Nov; 77(2):117-25. PubMed ID: 16271786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.